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Abstract
Respiratory distress syndrome is responsible for 40 to 60 percent mortality. An over mortality of about 10 percent could
result from additional lung injury and inflammation due to the life-support mechanical ventilation, which stretches the lung.
It has been recently demonstrated, in vitro, that pharmacological activation of the alpha 7 nicotinic receptors (a7-nAChR)
could down regulate intracellular mediators involved in lung cell inflammatory response to stretch. Our aim was to test in
vivo the protective effect of the pharmacological activation of the a7-nAChR against ventilator-induced lung injury (VILI).
Anesthetized rats were ventilated for two hours with a high stretch ventilation mode delivering a stroke volume large
enough to generate 25-cmH2O airway pressure, and randomly assigned to four groups: pretreated with parenteral injection
of saline or specific agonist of the a7-nAChR (PNU-282987), or submitted to bilateral vagus nerve electrostimulation while
pre-treated or not with the a7-nAChR antagonist methyllycaconitine (MLA). Controls ventilated with a conventional stroke
volume of 10 mL/kg gave reference data. Physiological indices (compliance of the respiratory system, lung weight, blood
oxygenation, arterial blood pressure) and lung contents of inflammatory mediators (IL-6 measured by ELISA, substance P
assessed using HPLC) were severely impaired after two hours of high stretch ventilation (sham group). Vagal stimulation
was able to maintain the respiratory parameters close to those obtained in Controls and reduced lung inflammation except
when associated to nicotinic receptor blockade (MLA), suggesting the involvement of a7-nAChR in vagally-mediated
protection against VILI. Pharmacological pre-treatment with PNU-282987 strongly decreased lung injury and lung IL-6 and
substance P contents, and nearly abolished the increase in plasmatic IL-6 levels. Pathological examination of the lungs
confirmed the physiological differences observed between the groups. In conclusion, these data suggest that the
stimulation of a7-nAChR is able to attenuate VILI in rats.
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Introduction
Mechanical ventilation is the main life-sustaining tool in Acute
Respiratory Distress Syndrome (ARDS), but even low tidal volume
strategies may cause the undesirable side-effects of cyclic hyper-
inflation of some lung areas [1]. Hyper-inflation of these areas
exposes the lung to ventilator-induced lung injury (VILI) which is
characterized by increased endothelial and epithelial permeability
and inflammatory processes [2]. Therefore, protection against
VILI appears essential.
Inflammatory processes involving lung cytokines could play a
major role in VILI. One of the systems regulating cytokine release
is the alpha7 nicotinic acetylcholine receptors (a7-nAChR). These
receptors are expressed on macrophages and epithelial cells [3]
and can be activated by acetylcholine released from efferent vagal
endings. The anti-inflammatory effect of the vagally-mediated
cholinergic pathway has been tested either in septic and non septic
models [4–12]. Fewer and contrasting data have been published
about lung inflammation [3,5,13]. In endotoxinic rats, Bernik et al.
have reported that vagal electrical stimulation was unable to
reduce pulmonary tumor necrosis factor synthesis whereas a
significant reduction was observed in serum and myocardium [5].
By contrast, data from Su et al. in mice exposed to acid-induced
acute lung injury or to Escherichia coli-induced lung injury
strongly suggest an anti-inflammatory effect of the vagally-
mediated cholinergic pathway at the lung level [3,13]. As for
VILI, we found only one in vivo report which supposes the
existence of an interaction between stretch-induced lung cytokine
release (20 mL/kg tidal volume) and the vagal anti-inflammatory
pathway [14]. In this above mentioned report, additional in vitro
experiments have also shown that specific agonist or antagonist of
the a7-nAChR acts on the intracellular mediators involved in cell
inflammatory response to stretch such as pJNK (pro-inflammatory)
and Fas, Daxx, pJNK and Bad (pro-apoptotic) [14]. However, the
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to be assessed in vivo.
The aim of the present study was to assess, in a rat model of
single-hit VILI, whether a pre-treatment with an agonist of the a7-
nAChR could attenuate the ventilator-induced impairment in lung
function. Furthermore, we examined whether improvement, if
any, was associated to a lower inflammatory response. We exposed
a group of rats to high stretch mechanical ventilation (HV) at a
stroke volume large enough to generate 25-cmH2O airway
pressure. In other groups, the same ventilation setting was applied
either during vagal electrostimulation or after pre-treatment with
the specific agonist of the a7-nAChR, PNU-282987. The airway
pressure and arterial blood gases were measured during the
experiments. The respiratory system compliance was measured at
the end, completed by further lung pathological examination and
lung IL-6 and substance P assays. Our data show that the
stimulation of the a7-nAChR was able to prevent lung impairment
in this animal model of VILI.
Methods
Animals
The experiments and protocols we used were in accordance
with the European law and its French version laid out in statutory
requirements for alive animal experiments (articles R214-87 to
R215-10 of Code Rural, law #76-629 from July 10
th, 1976/law
#2001-464 from May 29
th, 2001 (published in JORF on May 31
st,
2001). Conforming to these laws, the experiments were always
performed under direct control of holders of a name-specific
authorization delivered by Pre ´fecture-des-Bouches-du-Rhone ad-
ministration (authorization numbers #13-46 for SD and #13-437
for AR). All the interventions on animals conforming to the
guidelines laid out in the Guide for the Care and Use of
Laboratory Animals, were performed according to the require-
ments of the ethic committee of the Institut-Fe ´de ´ratif-de-
Recherche-Jean-Roche, Universite ´-de-la-Me ´diterrane ´e, and were
made in its rooms (institution permit number: #C13-055-8,
delivered by Pre ´fecture-des-Bouches-du-Rhone-Direction-De ´par-
tementale-des-Services-Ve ´te ´rinaires on January 30
th, 2007). Ac-
cording to the directive #2010/63/UE of the PARLEMENT
EUROPE ´EN and of the CONSEIL EUROPEEN published on
September 22
nd, 2010, about the protection of animals used for
scientific aims, no additional specific agreement number was
required for this study in non decerebrated rats, using euthanasia
under anesthesia plus analgesia for which animals were never
awakened in the course of the experiment.
Adult Sprague-Dawley male rats (n=49, mean body weight,
BW=427610 g) were anaesthetized with an intraperitoneal
mixture of sodium pentobarbitone (20 mg/kg) and ethyl-carba-
mate (0.5 g/kg). After tracheotomy, the left carotid artery was
catheterized for arterial blood pressure measurement (ABP) and
blood samplings (electromanometer Statham P23 Db, Puerto
Rico, Puerto Rico). An external jugular vein was cannulated for
drug injections. In every animal, both cervical vagus nerves were
dissected and exposed for further electro-stimulation or not.
To maximize lung injury following mechanical ventilation, rats
were exposed to HV by adjusting the stroke volume so that the
airway pressure (Paw) reached initially 25 cmH2O (HV25 groups).
These animals were assigned to four groups and were ventilated
for a maximum of two hours:
N One group was pre-treated with saline twenty minutes before
starting HV (one intra-peritoneal injection of 2.4 ml/kg plus
one intravenous injection of 1 mL/kg: HV25-sham group,
n=7). This group constituted the reference for VILI.
N One group had electrical stimulation of the cervical vagus
nerves before and during HV (HV25-stim group, n=7) in
order to confirm the efficiency of vagally-mediated protection
against this model of VILI.
N One group was pre-treated with the selective antagonist
methyllycaconitine (MLA) by a single intravenous injection
performed ten minutes before starting HV ventilation and
electrical stimulation of the vagus nerves (HV25-stim/MLA
group, n=7). This group aimed to examine if vagally-
mediated protection against VILI involved the a7-nAChR.
N One group was pre-treated with the selective a7-nAChR
agonist PNU-282987 injected intraperitoneally (2.4 mg/kg)
twenty minutes before starting high pressure ventilation
(HV25-PNU group, n=7). This aimed at testing whether the
activation of the a7-nAChR was protective independently of
vagal activation.
One group of rats ventilated for two hours with conventional
ventilation (10 mL/kg stroke volume, 7–8 cmH2O Paw and
positive end expiratory pressure at 1 cmH2O) was used for
reference data (Control group, n=7). Their main data are
reported in figure 1 and Table 1. The toxicity of MLA has been
related to neurological disorders resulting in tonic convulsions and
seizures followed by respiratory paralysis [15] but we have found
no report on its direct cardio-respiratory toxicity in literature.
However, we tested the possibility of a cardio-respiratory toxicity
of this molecule during ventilatory support in our model. Two
additional groups were performed, one receiving conventional
ventilation (Control-MLA group, n=7), another one receiving
HV (HV25-MLA group, n=7). In the Control-MLA group, minor
circulatory or respiratory changes were observed, similar to that
observed in Controls (Figure 1). In the HV25-MLA group, a
Figure 1. Time course of arterial oxygen partial pressure
(PaO2), airway pressure (Paw), and systolic arterial blood
pressure (ABP) in rats ventilated with conventional ventilation
and pre-treated with saline (Control) or methyllycaconitine
(Control-MLA). Data are presented as mean + SEM for ABP (lines and
plots) and Paw (plots). PaO2 is presented as box plots: the box
represents the 25 and 75 percentiles, mean and median are presented
as horizontal lines. No significant change was measurable.
doi:10.1371/journal.pone.0022386.g001
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differ from that of the HV25-sham group, showing a progressive
decrease in ABP and increase in Paw (see Figure S1 A). At the end
of the ventilation period, lung mechanics characteristics and lung
weight indexed to the body weight did not significantly differ
between both groups (see Figure S1 B, C, D).
Chemicals
The a7-nAChR agonist was the PNU-282987 (Tocris Biosci-
ence Ellisville, MO, USA), chosen for its selectivity [16]. It was
injected intraperitoneally at a dose of 2.4 mg/kg, previously
reported to be effective against lung inflammation in rodents [3].
The nicotinic receptor blocking agent methyllycaconitine (MLA),
more specifically the 3-methyl-2,5-dioxopyrrole (Sigma-Aldrich
Chemie. L’Isle d’Abeau Chesnes, St Quentin Fallavier France)
was also chosen for its selectivity [17] and was injected
intravenously at the previously reported single dose of 1 mg/kg
in rodents [18].
General procedure for injurious ventilation and electrical
stimulation
Ventilation was delivered via a small animal volume-controlled
ventilator (Harvard Rodent Ventilator Model 683). It was initially
started with a conventional stroke volume to generate 7–8 cmH2O
Paw for the first ten minutes. Then, high stretch ventilation was
achieved by increasing the stroke volume so that Paw reached
25 cmH2O and was left unchanged until the end of the
experiment. A 1-cmH2O end-expiratory pressure was applied.
The respiratory rate was fixed at 50 b/min. The pump delivered
room air enriched with CO2 via a low-flow flowmeter (Rota
Oeflingen flowmeter, Baden, Germany) to avoid hypocapnia. The
CO2 flow was adjusted to the arterial carbon dioxide partial
pressure (PaCO2) measurement and ranged between 10 and
50 mL/min whereas the minute ventilation of the animals was
approximately 500 mL/min. We controlled that the resulting
inspired oxygen fraction was not hypoxic: it ranged between 20
and 20.5 % (Rapidox 1100H gas analyzer, Cambridge Sensotec
Ltd, Cambs, England). In the HV25-stim and HV25-stim/MLA
groups, both cervical vagus nerves were placed on bipolar
platinum electrodes connected via an isolation unit to a Grass
S8800 stimulator. The characteristics of the square pulses were:
voltage=5–10 V, duration=2 ms, frequency=5–10 Hz and
were chosen according to previously published protocols [5,10].
Vagal stimulation started 10 min before the beginning of
mechanical ventilation and went on for the first ten minutes of
non injurious ventilation. Thereafter, vagal stimulation was
performed repeatedly for 10 min-periods with stimulation alter-
nating with 10-min periods without stimulation, to avoid nerve
damage by prolonged electrical stimulation. The effectiveness of
the vagal stimulation was attested by the characteristic transient
bradycardia and hypotension, named ‘vagal escape’ [19] (see
Figure S2). The vagally-induced bronchospasm was observed
when ventilation was not yet injurious (see Figure S3). When the
25 cmH2O Paw level had been reached, no further increase in
Paw could be detected during vagal stimulation, probably because
of the strong distension of airways and of an overlap of pressure
levels (as illustrated in Figure S2).
Continuous monitoring. As indexes of lung function
impairment, a decrease in blood oxygenation was expected on
repeated arterial blood gas analyses (Radiometer ABL 330,
Copenhagen) and a Paw increase was checked on the
continuous monitoring (Gould TA 4000, Ballinviliers, France). A
cardiovascular monitoring was also continuously performed.
Lung mechanics assessment. The rats were euthanized
after two hours of ventilation by an intravenous overdose of 5 %
sodium pentobarbitone or died spontaneously. Post-mortem
volume-pressure relationships were determined for further
calculation of the inspiratory compliance of the respiratory
system (Crsi) indexed to the body weight (Crsi/BW). Then, the
trachea was clamped at end-inspiration (inflated at 8 mL/kg)
before sternotomy. The gross vessels were cut and blood passively
emptied. The left lung was filled with 10% buffered formalin for
histological analysis. The right lung was weighed and divided into
three fragments that were frozen for further biochemical assays.
Histological analysis. Fixed lungs were divided in three
equal parts from the apex to the bottom, defined as cranial, middle
and caudal. Slices of three micrometers were made in the median
part of each section, including the whole circumference of the
lung. Two pathologists blinded to the group assignment examined
the slides. As previously described [20], they quantified the five
following histological criteria: edema, interstitial inflammatory cell
infiltration, intra-alveolar inflammatory cell accumulation,
hemorrhage and hyaline membranes. Their respective intensity
was scored as zero (absent), + (mild), ++ (moderate), +++ (severe)
and ++++ (very severe). The intensities obtained on each of the
three slides were summed up (maximum=12). A total composite
score was calculated by adding the score of each representative
criterion.
Enzyme-Linked Immunosorbent Assay Measurements.
The IL-6 levels were measured in the supernatant of homogenized
lung extracts and in plasma with sensitive Enzyme-Linked
Table 1. Variables measured after mechanical ventilation with conventional ventilation (controls) or after high stretch ventilation.
groups Final PaO2, mmHg Lung weight/body weight, g/kg Crsi/BW, mL/cmH2O/kg
Controls 11464 2.10 [1.94–2.21] 1.6060.19
HV25-sham 6667 5.10 [4.21–5.90] 0.3560.11
HV25-PNU 9062** 2.21 [2.00–2.30]*** 1.6760.14***
HV25-stim 8865* 2.53 [2.18–3.14]*** 1.2960.12***
HV25-stim/MLA
(at 45 minutes)
2163*** 6.29 [2.72–8.68] 0.1660.02
Crsi/BW: static compliance of the respiratory system measured on inflation and indexed to the body weight. HV25-sham: injurious ventilation and saline injection.
HV25-stim: injurious ventilation associated with bilateral electro-stimulation of the cervical vagus nerves. HV25-stim/MLA: injurious ventilation associated with
bilateral electro-stimulation of the cervical vagus nerves and pre-treatment with alpha7 nicotinic acetylcholine receptor blocking agent MLA. HV25-PNU : injurious
ventilation associated with pre-treatment with alpha7 nicotinic acetylcholine receptor agonist PNU.
*, ** and ***: respectively p,0.05, ,0.01 and ,0.001 versus HV25-sham.
doi:10.1371/journal.pone.0022386.t001
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Fisher Scientific, Perbio Science France SAS, Brebie `res, France) and
using the StatFax 3200 microplate reader (Awareness Technology Inc.,
Palm City, FL, USA).
Substance P (SP) extraction and detection. The
tachykinin SP, possibly from neuronal and non neuronal origin
in rat lungs [21], acts as a pro-inflammatory mediator and was
previously reported to increase with the level of lung stretch and
injury [22]. We used this molecule as a complementary marker of
lung inflammation in our model. Detection and quantification
were performed using high-performance liquid chromatography
(HPLC, Onyx) on lyophilized lung extracts (1 mg per run) as
previously described [22]. The area under the SP peak
chromatogram was expressed in arbitrary units and used for
comparisons. Scattering of data measured by SD coefficient
corresponds to that of repeated measurements in the same
aliquot collected from all individuals in each group.
Statistics
The SigmaStat 3.0 program (Sigma Company, SPSS Inc.,
Erkrath, Germany) was used. Data were tested for normal
distribution with the Kolmogorov-Smirnov test. When data
distribution of continuous variables was not normal, median and
quartile values were given in the text and individual data or box
plots (median and quartile values) were presented in the figures.
When data were normally distributed, we used mean 6 SEM in
the text and figures.
For most of the temporally repeated data, the changes over time
were assessed in each group using a mixed-design analysis of
variance model for repeated measures (mixed-design ANOVA
model including between-subjects variable and random effect). In
case of significant difference, Holm-Sidak comparison versus the
first time with high pressure ventilation was performed. Multiple
comparisons between groups were performed, using two-way
ANOVA (treatment, individuals) or Mann-Whitney’s rank sum
test when appropriate. They were followed by Holm-Sidak
comparison versus HV25-sham group in animals that survived
for the 2-h period of the experiment, except for the HV25-stim/
MLA group in which the animal died prematurely. A p value
#0.05 was used to determine statistical significance.
Results
Ventilator-induced lung injury
In animals exposed to HV, the average tidal volume indexed to
the body weight was 24.3360.21 mL/kg (corresponding to
10.3060.20 mL), with no significant difference between groups.
Figure 2. Time course of airway pressure (Paw, panel A) and
arterial oxygen partial pressure (PaO2, panel B), in animals
exposed to high stretch ventilation. HV25-sham: animals exposed
to 25 cmH2O Paw only. HV25-stim: animals exposed to 25 cmH2O Paw
and receiving vagal stimulation. HV25-stim/MLA, vagal stimulation was
associated to a pre-treatment with a specific antagonist of the alpha7
nicotinic acetylcholine receptor, methyllycaconitine (MLA). HV25-PNU:
animals exposed to 25 cmH2O Paw and pre-treated with the alpha7
nicotinic acetylcholine receptor agonist PNU. Levels of significance
versus HV25-sham are indicated on the graphs or by asterisks:
** p,0.01.
doi:10.1371/journal.pone.0022386.g002
Figure 3. Comparative arterial blood carbon dioxide partial
pressure (PaCO2, plots) and arterial pH (bars) in groups
exposed to high stretch ventilation. HV25-sham: animals exposed
to 25 cmH2O Paw only. HV25-stim: animals exposed to 25 cmH2O Paw
and receiving vagal stimulation. HV25-stim/MLA, vagal stimulation was
associated to a pre-treatment with a specific antagonist of the alpha7
nicotinic acetylcholine receptor, methyllycaconitine (MLA). HV25-PNU:
animals exposed to 25 cmH2O Paw and pre-treated with the alpha7
nicotinic acetylcholine receptor agonist PNU. Symbol $ indicates
significant differences versus baseline in a same group. Symbol *
indicates significant differences versus HV25-sham group at the same
time.
doi:10.1371/journal.pone.0022386.g003
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the body weight was 10.2560.02 mL/kg (corresponding to
4.2760.01 mL). At the fixed stroke volume, the HV25-sham
group showed a progressive increase in Paw with time (figure 2
panel A) and a decrease in blood oxygenation (figure 2 panel B)
while the PaCO2 was maintained in the normal range for all
groups throughout the study period (figure 3).
At the end of the experiments, HV25-sham animals had higher
lung weight and lower respiratory system compliance than what
was measured in the controls (Table 1). HV25-stim animals had
significantly better lung mechanical properties than the HV25-
sham ones (no measurable alteration of Crsi/BW and absence of
increased Paw from the beginning of injurious ventilation), better
gas exchange and lower lung weight (Table 1 and figure 2).
Figure 4 shows that the volume-pressure relationship of the non-
protected group (HV25-sham) shifted to the right, attesting of
impaired lung mechanical properties, while it was close to that of
controls in the HV25-stim group.
On the contrary, lung damage worsened in the HV25-stim/
MLA group (Table 1, figure 2) and the shift to the right of the
volume-pressure relationship of this group was even more
pronounced than that observed in the HV25-sham group (figure 4).
Animals receiving direct a7-nAChR activation (HV25-PNU
group) did not develop any significant physiological change in lung
function (figure 2, Table 1). In a similar way to the HV25-stim
group, the volume-pressure relationship of the HV25-PNU group
did not clearly shift to the right (figure 4).
Hemodynamics
A decrease in arterial pH was observed in all HV25 animals
(figure 3). It reached statistical significance at the 120 min-period
in the HV25-sham and the HV25-stim groups, did not reach
statistical significance in the HV25-PNU group and was more
pronounced and appeared earlier in the HV25-stim/MLA group
than in the other groups. Concordantly, all groups but the HV25-
PNU group had a progressive fall in systolic ABP (figure 5).
Compared to HV25-sham rats, the HV25-stim animals tended to
have a less pronounced fall but the difference did not reach
statistical significance (end, systolic ABP=8963 mmHg in the
HV25-stim group and 6969 mmHg in the HV25-sham group).
The outcome was particularly impaired in the HV25-stim/MLA
group, (final systolic blood pressure=4665 mmHg (figure 5),
associated to bradycardia, and premature deaths occurred in a
context of cardio-respiratory failure (figure 5 and table 1).
Inversely, systolic ABP remained above 100 mmHg in the
HV25- PNU group, contrary to that observed in HV25- sham
animals (at the end, systolic ABP=134610 mmHg in the HV25-
PNU group, p,0.01 versus HV25-sham group).
Lung inflammation
Pathological examination showed that inflammatory cell
infiltration and edema caused by injurious ventilation (HV25-
sham group) were present but minimized in the HV25-PNU group,
weakly but significantly more pronounced in the HV25-stim group
and increased in the HV25-stim/MLA group. The criteria of
inflammation were the most discriminating. Only few cases of
hemorrhage were observed: they concerned only the HV25-sham
and HV25-stim/MLA groups. Hyaline membranes were absent.
Edema, intra-alveolar cell accumulation and interstitial inflam-
matory cell infiltrates were the three selected criteria for the total
composite score (sum of the two obtained intensities, minimum
Figure 4. Respiratory system compliance. The pressure-volume
curves during inflation in rats exposed to high stretch ventilation show
the rightward shift and a lower inflection point (arrows) in unprotected
groups. The reference curve from animals ventilated with non-injurious
ventilation for two hours is also shown (Control). HV25-PNU: pre-
treated with alpha7 nicotinic acetylcholine receptors agonist PNU
(empty circles). HV25-stim: associated with vagal electrostimulation
(empty reversed triangles). HV25-sham: pre-treated with saline (plain
circles). HV25-stim/MLA: associated with vagal electrostimulation and
pre-treatment with alpha7 nicotinic acetylcholine receptor blocking
agent MLA (plain reversed triangles)
doi:10.1371/journal.pone.0022386.g004
Figure 5. Time course of cardio-circulatory variables in animals
exposed to high stretch ventilation. Heart rate (HR) and systolic
arterial blood pressure (ABP) in animals ventilated at 25 cmH2O airway
pressure only (HV25-sham), or associated with vagal stimulation (HV25-
stim) or a specific antagonist of the alpha7 nicotinic acetylcholine
receptor, methyllycaconitine (MLA) (HV25-stim/MLA), or without vagal
stimulation but pre-treatment with the alpha7 nicotinic acetylcholine
receptor agonist PNU (HV25-PNU). *p,0.05, ** p,0.01; *** p,0.001
versus HV25-sham.
doi:10.1371/journal.pone.0022386.g005
Alpha7 Nicotinic Receptor Agonism Prevents VILI
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stim and HV25-PNU groups (figure 6 panels A and B).
Representative pathological slides are presented in figure 7.
As shown in figure 8, both HV25-stim and HV25-PNU groups
had a strong reduction in lung IL-6 concentration when compared
to the HV25-sham group (median [25–75 percentiles], ng/g : 66.9
[25.6–79.5] in HV25-sham versus 2.2 [2.0–2.4] in controls,
p,0.001). The SP lung content was also reduced (figure 8).
Plasma levels of IL-6 are presented in figure 8 panel B. Among
the groups in which animals survived for 2 hours, the HV25-PNU
group was the only one to show a significant final decrease in IL-6
plasma level when compared to the HV25-sham group (median
[25–75 percentiles], pg/mL: 1309.0 [1276.0–1456.0] versus 40.6
[36.3–45.0] in HV25-PNU,p ,0.001). It must be noticed that in the
HV25-stim/MLA group, the plasma was sampled earlier because
of premature deaths (,60 min.) which explains lower final IL-6
amounts (bias due to the lower duration of exposition).
Discussion
The present work confirms that high stretch ventilation applied
for 2 hours induces lung injury and inflammation in rats. In this
model, vagal electro-stimulation or pre-treatment with a selective
agonist of the a7-nAChR, limited largely these consequences.
Conversely, after blockade of the a7-nAChR, vagal stimulation
failed to protect and lung damage was even more intense. These
results confirm the existence of a vagally mediated reduction in
VILI through the cholinergic nicotinic pathway. Besides, by using
a uniformly designed experiment in rats, we originally demon-
strate in vivo the preventive effect of a pre-treatment with a a7-
nAChR agonist.
The involvement of the a7-nAchR has been recently demon-
strated in vitro in a study showing reduction in cell stretch-induced
inflammation and apoptosis [14]. We reinforced its findings by
demonstrating that activation of the a7-nAchR by a specific
Figure 6. Lung injury scores in rats exposed to high stretch ventilation. Panel A represents individual score, panel B represents composite
score. HV25-sham: injurious ventilation and saline injection; HV25-PNU: pre-treated with alpha7 nicotinic acetylcholine receptors agonist PNU;
HV25-stim: associated with vagal stimulation; HV25-stim/MLA: associated with vagal stimulation and pre-treatment with alpha7 nicotinic
acetylcholine receptor blocking agent MLA. Data are expressed as mean 6 SEM. Levels of significance are indicated on the graph.
doi:10.1371/journal.pone.0022386.g006
Alpha7 Nicotinic Receptor Agonism Prevents VILI
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tion provoked by lung stretch in vivo. Surprisingly, the protection
reported here with the a7-nAchR agonist was nearly complete,
whereas it was only mitigated with a global pharmacological
activation of the vagus nerve in mice [14]. Such a more intense
effect could be due in part to our different animal model (rats), to
the avoidance of hypocapnia, which is known to favor VILI [23],
and to our shorter length of exposition to high stretch ventilation
(two versus three hours). Although we didn’t demonstrate or study
it here, the specific a7-nAchR activation with PNU-282987 was
perhaps more powerful than with a global vagomimetic drug such
as CNI-1493 [24]. One may however wonder about PNU-282987
efficiency over the study period since its half life has not yet been
reported in rats following intraperitoneal injection. We think it
unlikely that PNU-282987 had become fully inactive after two
hours, because it has a high affinity for the a7 nicotinic
acetylcholine receptors and its half life value in vitro is .120
minutes [25].
Since IL-6 concentrations were a hundred-fold higher in lung
than in plasma, it is highly likely that IL-6 was mainly lung borne.
The similar plasma concentrations of IL-6 observed in the HV25-
sham and HV25-stim groups may result from a peripheral
production in response to the cardio-vascular deterioration due
to high thoracic pressures, with subsequent tissue hypoperfusion.
The a7-nAChR agonist injected into the systemic circulation
seemed able to decrease the IL-6 production in the whole
organism, perhaps because of a better hemodynamics, or because
of a down-regulation applied to the whole organism in opposition
to the vagal stimulation which should have released acetylcholine
into the thoraco-abdominal organs only.
Because there is a large spread of vagal innervation into the lung
[26], acetylcholine can be released from efferent vagus nerves all
along the respiratory system, from the trachea to the respiratory
bronchioles. Some reports demonstrate that a7-nAChR are
expressed by various non-neuronal cells [27,28], especially lung
macrophages and alveolar type II cells [3], these cells being thus
the possible targets for acetylcholine binding. Some inhibitory
signaling pathways have been experimentally highlighted suggest-
ing how activation of the a7-nAChR may downregulate
inflammation. For instance, in human monocytes stimulated with
Figure 7. Lung histopathology of animals exposed to high stretch ventilation. Hematoxylin-eosin-saffron stained sections. Original
magnification of pictures x50; original magnification of insets x100. The intra-alveolar inflammation with alveolar macrophages can be seen in the
HV25-sham slide and, at a lesser level, in the HV25-stim slide. Note the alveolar polymorphonuclear leukocytes in addition to the macrophages in HV25-
stim/MLA group. By contrast, no intra-alveolar inflammatory cell accumulation was seen in the HV25-PNU group. In every group, the inter-alveolar
walls were moderately edematous and inflamed with inflammatory mononuclear cells. The alveolar edema is here especially marked on the HV25-
sham slide.
doi:10.1371/journal.pone.0022386.g007
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suppressed NF-kB nuclear translocation and I-kB phosphoryla-
tion, and, in mouse macrophages previously activated by intestinal
manipulation, the acetylcholine released during vagus nerve
stimulation activated the inflammation-inhibitory JAK2/STAT3
pathway. Both experimental situations resulted in downregulation
of pro-inflammatory cytokines, including IL-6 [8,29,30]. In the
present work, global vagal stimulation or specific pharmacological
activation of the a7-nAChR minimized the adverse effects of high
stretch ventilation and strongly decreased lung IL-6 and SP
contents. IL-6 has been known to be downregulated by the
cholinergic anti-inflammatory pathway since the princeps article of
Borovikova et al. [6]. On the other hand, SP is a well known
inflammatory mediator. Whether a7-nAChR directly interacts
with SP would need specific studies and has not been assessed in
the present work. A link has been shown between SP and cytokines
Figure 8. Concentrations of lung and plasma IL-6 and lung substance P contents after high pressure ventilation. IL-6 in lung extracts
(top panel) and in plasma (middle panel), measured by ELISA. SP lung contents assessed by HPLC (bottom panel). Individual (circles) and median
(horizontal bars) values are indicated for IL-6. SP is presented as mean values (solid bars) and standard error. HV25-sham: injurious ventilation.
HV25-stim: injurious ventilation associated with vagal stimulation. HV25-stim/MLA: injurious ventilation associated with vagal stimulation and pre-
treatment with the alpha7 nicotinic acetylcholine receptor blocking agent MLA. HV25-PNU: injurious ventilation associated with pre-treatment with
the alpha7 nicotinic acetylcholine receptors agonist PNU. Asterisks indicate significant differences versus HV25-sham group (*p,0.05, ** p,0.01;
*** p,0.001).
doi:10.1371/journal.pone.0022386.g008
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cytokines, especially IL-6 [31]. Reciprocally, cytokines injected
into the lung (especially IL-1 beta but possibly IL-6), can activate
SP containing C-fibers [32,33]. Therefore, the a7-nAChR
activation could decrease indirectly the SP amounts through a
lower cytokine release by the cells expressing this receptor.
The reduction in stretch-induced lung damage measurable both
on the physiological and pathological levels could result partly
from the inhibition of cytokine/SP release, but not only. As
discussed above, the less pronounced fall in blood pressure of the
animals receiving PNU may have favored less cytokine release
(especially in plasma). In this group, a preservation of cardiovas-
cular function, as suggested from blood pressure, heart rate, and
pH data, may also have contributed to lower lung weight. On the
other hand, the knowledge of biological and functional effects of
a7-nAChR activation is only starting. Some reports suggest its
involvement in systemic vascular tone [34] or pulmonary vascular
permeability [3]. The possibility of a beneficial effect of a7-
nAChR activation, for example on pulmonary perfusion, vascular
permeability or cardio-vascular tone, cannot be discarded. In the
HV25-stim group, some degree of lung injury remained: there was
a larger range of lung weight values and a persistency of lung
pathological abnormalities. Despite the fact that crude lung weight
is not a very sensible index, it was corroborated by data on
compliance and pathological findings. In the HV25-stim group,
repeated periods of bradycardia and hypotension may have
induced heart failure, which could have generated some degree of
lung edema and only partial protection against inflammation. In
this group, the cardiovascular consequences of vagal stimulation
were probably underestimated because we recorded the heart rate
and arterial pressure values once vagal stimulation had been
stopped. This could explain the significantly lower pH value at 60
minutes in this group (metabolic acidosis). In addition, a specific
inflammatory effect of vagal stimulation on airways could have
contributed to the lung inflammation in this group [35] explaining
the incomplete protection with regard to inflammation.
The idea of a strong protective role of the a7-nAChR was
reinforced by the observation of a worsening in lung damage when
vagal stimulation was preceded by a7-nAChR blockade with
MLA. The reasons for such a worsening can only be speculative.
We previously reported that the vagus nerve participates in lung
SP release and injury during high stretch ventilation [22]. The
stimulation of the whole vagus nerve releases SP retrogradely from
afferent C-fibers [36,37] and, orthodromically, acetylcholine from
efferent fibers [26]. It is possible that, in the HV25-stim group, the
cholinergic anti-inflammatory pathway had downregulated the
stretch-induced inflammatory response since the a7-nAChR were
reachable. With a7-nAChR blockade coupled to vagal stimula-
tion, a possible vagally-mediated SP increase may have increased
inflammation [38]. Because lung SP amounts may result both
from neurogenic (vagal) and non-neurogenic (immune cells)
sources, it is not surprising that lung SP was reduced in the
HV25-stim group given the anti-inflammatory effect of the
cholinergic pathway. MLA can also inhibit a population of non-
a7-nAChR such as a4b2-nAChR [39], which has also been
involved in anti-inflammatory processes [40]. The fact that the
enhanced injury observed in the HV25-stim /MLA group could
result partly from the blockade of these other receptors should
therefore not be discarded. Another possible explanation for
worsening in the HV25-stim/MLA group is based on basic
physiological knowledge: heart activity depends on the balance
between the inhibitory effects of the parasympathetic innervation
and the stimulatory effects of the sympathetic innervation. The a7-
nAChR also mediates autonomic ganglionic transmission [41] and
its blockade can prevent increase in sympathetic cardio-vascular
activity [18]. Therefore, in our experiment, the reported
premature deaths with cardio-circulatory failure in the HV25-
stim/MLA group could result from the inability of the sympathetic
system to counterbalance the vagally-induced inotropic and
bathmotropic negative effects, as suggested by the bradycardia
reported in figure 5. The half life of MLA being about 20 minutes
in rats after intravenous injection [42], we think it likely that
efficient concentrations of this drug were still present in the plasma
of the HV25-stim/MLA group at the time of death, occurring at
twice the half life.
The present study confirms the previously suggested modulation
of lung inflammation by the cholinergic anti-inflammatory
pathway in the lungs exposed to VILI. Selective pharmacological
stimulation of the a7-nAChR appears efficient in preventing VILI
and might be a new pharmacological target, especially in ARDS
patients at risk for ventilator associated injury. However, further
experiments with longer duration of mechanical ventilation and
applied to larger animal models would be required to confirm the
benefits observed.
Supporting Information
Figure S1 Comparison between HV25-sham animals
(large volume ventilation generating 25 cmH2O airway
pressure and saline injection) and HV25-MLA (large
volume ventilation generating 25 cmH2O airway pres-
sure and pre-treatment with alpha7 nicotinic acetylcho-
line receptor blocking agent MLA). Data are expressed as
mean 6 SEM. Panel A: time course of systolic arterial blood
pressure (bars), and of airway pressure (line and plots), in animals
exposed to high stretch ventilation. Paw: airway pressure. The
changes over the time were significant versus baseline in both
groups but no significant difference between the two groups was
detected. Panel B: pressure-volume relationships. Paw: airway
pressure. Panel C: weight of the right lung indexed to the rat body
weight as measured at the end of the injurious ventilation period;
ns : no significant difference. Panel D: compliance of the
respiratory system measured at inflation (Crsi) indexed to the rat
body weight (Crsi/BW); ns : no significant difference.
(TIF)
Figure S2 Example of the response to the bilateral
stimulation of the cervical vagus nerves during high
stretch ventilation. Upper and lower tracings represent
respectively the airway pressure (Paw) and the arterial blood
pressure (ABP). The bold horizontal arrow represents the
beginning of a 10-min period of electrical stimulation. Peripheral
vagal stimulation induced bradycardia and hypotension attesting
its remaining functional efficacy, in this case, 90 min after the start
of the experiment. It must be noted that cardiovascular changes
partly adapted when vagal stimulation was continued (parasym-
pathetic overdrive). The Paw remained at 25 cmH2O during the
vagus nerve stimulation.
(TIF)
Figure S3 Example of the responses to the bilateral
stimulation of the cervical vagus nerves before injurious
ventilation, i. e. during the conventional ventilation
applied for the first ten minutes of the experiment in one
HV25-stim rat. Upper and lower tracings represent respectively
the airway pressure (Paw) and the arterial blood pressure (ABP).
The bold horizontal line represents the electrical stimulation. The
recording was performed just after the injection of the neuromus-
cular blocking agent and some residual spontaneous inspirations
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e22386generated negative Paw waves. In parallel to the hypotention, an
increase in airway pressure (Paw) can be observed, attesting of the
vagally-induced bronchospasm.
(TIF)
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